Safety Study of SMOFlipid to Evaluate the Risk of Developing EFAD and/or PNAC in Pediatric and Adult Patients
NCT06049680 is a phase 4 interventional trial sponsored by Fresenius Kabi. As of 21 Nov 2026, it is recruiting participants. It studies SMOFlipid® in Essential Fatty Acid Deficiency (EFAD), Malnutrition and 2 more conditions. The registry lists an enrollment of 100 participants at 6 sites in 1 country. The registry lists a start date of 28 Oct 2024 and a primary completion date of 30 Nov 2026.
Key facts
Registry attributes as recorded on the ClinicalTrials.gov study record.
| Field | Value |
|---|---|
| Registry ID | NCT06049680 |
| Status | Recruiting |
| Phase | Phase 4 |
| Study type | Interventional trial |
| Lead sponsor | Fresenius Kabi |
| Enrollment | 100 |
| Registered sites | 6 |
| Countries | 1 |
| Conditions | Essential Fatty Acid Deficiency (EFAD), Malnutrition, Malnutrition, Child and Parenteral Nutrition Associated Cholestasis |
| Drugs | SMOFlipid® |
| Start | 28 Oct 2024 |
| Primary completion | 30 Nov 2026 |
| Study completion | 31 Jan 2027 |
| Last update posted | 22 Oct 2026 |
Registered summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Jeffrey Rudolph, MD
University of Pittsburgh
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
6 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Emory University Hospital
Atlanta
Recruiting
- the University of Chicago
Chicago
Terminated
- Riley Hospital for Children
Indianapolis
Recruiting
- Duke University Medical Center
Durham
Not, yet, recruiting
- Nationwide Children's Hospital
Columbus
Recruiting
- Children's Hospital of Pittsburgh of Upmc
Pittsburgh
Recruiting
United States, by state
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Questions about NCT06049680
Each answer restates registry values shown on this page.
What is NCT06049680?
NCT06049680 is a phase 4 interventional trial sponsored by Fresenius Kabi. It studies SMOFlipid® in Essential Fatty Acid Deficiency (EFAD), Malnutrition and 2 more conditions.
Is NCT06049680 recruiting?
As of 21 Nov 2026, it is recruiting participants. 4 of its 6 sites list their own status as recruiting.
Who leads NCT06049680?
The registry names Jeffrey Rudolph, MD (principal investigator, University of Pittsburgh) as the overall official.
Where does NCT06049680 run?
The registry lists 6 sites in 1 country. Every site with a stated country is in one country: United States.
Which drugs does NCT06049680 study?
The registered drug and biological interventions are SMOFlipid®.
When is NCT06049680 expected to complete?
The registry lists a primary completion date of 30 Nov 2026 and a study completion date of 31 Jan 2027. The sponsor last updated the record on 22 Oct 2026.
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.